ERBB2 and non-small cell lung carcinoma: Cappuzzo and colleagues published the first successful report of treatment of a patient with a HER2 mutant NSCLC with trastuzumab in 200686, and retrospective data from the European EUHER2 trial cohort of relapsed NSCLC with HER2 mutations support this approach, with an observed ORR of 50% and a PFS of 4.8 months in the trastuzumab plus chemotherapy group70.